title: PAF acether release on antigenic challenge. A method for the investigation of drug allergic reactions.
abstract: This study describes an in vitro method to evaluate a PAF acether release test (PART) from white blood cells after antigenic challenge. PAF acether activity of the supernatant was tested by platelet aggregation. The aggregating power was abolished by using SRI 63-441 (Sandoz), a PAF acether inhibitor. This method was applied to 57 patients with allergic or pseudo-allergic reactions to drugs by using different drug protein conjugates. The results of PART were evaluated in relation to the clinical history (score of imputability) and to other tests (skin tests, lymphocyte transformation tests (LTT), IgE-RAST). A good correlation was found between the release of PAF acether and a high predictability score: sensitivity 75%, specificity 83.8%. PART also correlated with skin tests (75% agreement, n = 60), with LTT (67.7% agreement, n = 74) and in 65.6% of cases with positive penicillin IgE-RAST (n = 32). This method brings a new possibility for the investigation of drug-allergic and pseudo-allergic reactions.
authors.affiliation: University Cantonal Hospital of Geneva, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Dunoyer-Geindre
authors.forename: F
authors.initials: F
authors.lastname: Ludi
authors.forename: T
authors.initials: T
authors.lastname: Perez
authors.forename: N
authors.initials: N
authors.lastname: Terki
authors.forename: P I
authors.initials: PI
authors.lastname: Gumowski
authors.forename: J P
authors.initials: JP
authors.lastname: Girard
mesh_terms: D000941:Antigens / Q000276:immunology*; D001241:Aspirin / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000097:blood / Q000175:diagnosis* / Q000378:metabolism; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D007962:Leukocytes / Q000378:metabolism; D008012:Lidocaine / Q000009:adverse effects; D008213:Lymphocyte Activation; D010406:Penicillins / Q000009:adverse effects; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010974:Platelet Aggregation; D011237:Predictive Value of Tests; D011806:Quinolinium Compounds / Q000494:pharmacology; D011852:Radioallergosorbent Test; D012680:Sensitivity and Specificity; D012882:Skin Tests; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects
chemical_list: D000941:Antigens; D010406:Penicillins; D010972:Platelet Activating Factor; D011806:Quinolinium Compounds; C050531:SRI 63-441; D007073:Immunoglobulin E; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D008012:Lidocaine; D001241:Aspirin